OpenLB
Open Library of Bioscience

Thirty years of therapeutic innovation in melanoma research.

Abstract

No abstract text available.

References

1. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 2006; 16:97–103.
2. Flaherty KT. Targeting signal transduction pathways in melanoma. Melanoma Res. 2010; 20:e20.
3. Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, et al. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Res. 2014; 24:415–418.
4. Schreuer M, Meersseman G, van Den Herrewegen S, Jansen Y, Seremet T, Bott A, et al. Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Res. 2016; 26:157–163.
5. Bowyer SE, Rao AD, Lyle M, Sandhu S, Long GV, McArthur GA, et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res. 2014; 24:504–508.
6. Robert C, Thomas M, Mateus C. MAP-kinase pathway up or down? Just look at the skin of your patients! Melanoma Res. 2014; 24:421–423.
7. Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, et al. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res. 2014; 24:496–500.
8. Latimer NR, Amonkar MM, Stapelkamp C, Sun P. Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Res. 2015; 25:528–536.
9. Storkus WJ. Melanoma vaccines: in search of a clinical paradigm. Melanoma Res. 2007; 17:137–138.
10. Weber WS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res. 2006; 16:379–383.
11. Hodi F, Seiden M, Butler M, Haluska F, Kruse A, Mac Rae S, et al. CTLA-4 blockade induces effective anti-tumor immunity without significant autoimmunity in previously vaccinated patients. Melanoma Res. 2006; 16:S34–S35.
12. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, Lebbé C. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 2010; 20:247–250.
13. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res. 2009; 19:333–334.
14. Schreuer MS, Chevolet IL, Jansen YJ, Seremet TC, Wilgenhof S, Liénard D, et al. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res. 2015; 25:68–74.
15. Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, et al. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017; 27:24–31.
16. Postow MA, Chasalow SD, Kuk D, Panageas KS, Cheng ML, Yuan J, Wolchok JD. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Res. 2020; 30:71–75.
17. Ladwa R, Atkinson V. The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Res. 2017; 27:168–170.
18. Lüttmann N, Grätz V, Haase O, Eckey T, Langan EA, Zillikens D, Terheyden P. Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res. 2016; 26:528–531.
19. Ouwerkerk W, van den Berg M, van der Niet S, Limpens J, Luiten RM. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Res. 2019; 29:453–464.
20. Failing JJ, Yan Y, Porrata LF, Markovic SN. Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Melanoma Res. 2017; 27:596–600.
21. Lejeune FJ (ed). Recent experience with immune checkpoint and kinase inhibitors shows significant and unexpected side-effects. Melanoma Res. 2018; 28:489–490.
22. Menshawy A, Eltonob AA, Barkat SA, Ghanem A, Mniesy MM, Mohamed I, et al. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. Melanoma Res. 2018; 28:371–379.
23. Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, et al. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021; 31:67–75.
24. Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, et al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Res. 2016; 26:284–289.
25. Wind TT, Gacesa R, Vich Vila A, de Haan JJ, Jalving M, Weersma RK, Hospers GAP. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Res. 2020; 30:235–246.
26. Blankenstein SA, van Akkooi ACJ. Adjuvant systemic therapy in high-risk melanoma. Melanoma Res. 2019; 29:358–364.
27. Grogan N, Swami U, Bossler AD, Zakharia Y, Milhem M. Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res. 2018; 28:600–604.
28. Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res. 2019; 29:178–186.
29. Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020; 30:364–375.
30. Maurer DM, Butterfield LH, Vujanovic L. Melanoma vaccines: clinical status and immune endpoints. Melanoma Res. 2019; 29:109–118.

MeSH Term